![]() |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Liste des catégories
AlcoolismeAlzheimer Et ParkinsonAnalgésiquesAnti-inflammatoiresAntiallergiquesAntibiotiquesAnticonvulsivantsAntidépresseursAntifongiquesAntiparasitairesAntivirauxArthriteAsthmeCancerChirurgieCholestérolContraceptifsDiabèteDiurétiquesDysfonction érectileHypertension ArtérielleMaladies CardiovasculairesMigrainesObésitéOstéoporoseRelaxants MusculairesSanté FéminineSanté MasculineSoins De La PeauSoins Des YeuxTractus Gastro-intestinalTroubles MentauxTroubles NeurologiquesV I HVoies RespiratoiresVoies Urinaires 18 May 2012 11:05:00
Υπερτιμημένα τα φάρμακα στην αγορά θ micardis , , θ 4,20 θ 28 micardis 40mg 80mg, ...03 May 2012 12:52:26
Boehringer Ingelheim reports successful 2011 business yearBoehringer Ingelheim reports successful 2011 business year Zenopa Around 77 percent of this revenue total was accounted for by prescription medicines, with the 2011 launch of Pradaxa proving instrumental in the company's growth, while established therapies such as Spiriva, Micardis and Combivent also contributed.
30 Apr 2012 09:10:27
Switching to TWYNSTA® allows patients with uncontrolled hypertension on ...Switching to TWYNSTA allows patients with uncontrolled hypertension on ... EON: Enhanced Online News (press release) Telmisartan is currently registered in 112 countries and marketed in 104 countries worldwide under the tradenames Micardis , Pritor , and Kinzalmono . Telmisartan is marketed in cooperation with Astellas Pharma Inc. in Japan, Bayer HealthCare in ...
26 Apr 2012 09:51:17
Boehringer Ingelheim eleva sus ventas un 6,2%Boehringer Ingelheim eleva sus ventas un 6,2% La Vanguardia Tanto el nuevo lanzamiento en el mercado de Pradaxa, como los medicamentos bien establecidos como Spiriva, Micardis y Combivent, presentan un crecimiento muy positivo , afirm Hubertus von Baumbach, miembro del Comit Ejecutivo Internacional y ... BI dej en un accidente el baj n de 2010 con un aumento del 4,6% en sus ventas
25 Apr 2012 17:05:41
Boehringer Ingelheim, en vía de crecimientoBoehringer Ingelheim, en v a de crecimiento PR Noticias (Comunicado de prensa) Tanto el nuevo lanzamiento en el mercado de Pradaxa , como los medicamentos bien establecidos como Spiriva , Micardis y Combivent , presentan un crecimiento muy positivo , afirm Hubertus von Baumbach, miembro del Comit Ejecutivo Internacional y ...
25 Apr 2012 12:36:34
'Boring' Boehringer beats the market as Pradaxa shines'Boring' Boehringer beats the market as Pradaxa shines Pharma Times The blood pressure drug Micardis (telmisartan) rose 2.4% to 1.59 billion euros, while its other COPD treatment Combivent (ipratropium and albuterol) contributed 766 million euros, up 5.4%. However the most striking performance came from Pradaxa ...
25 Apr 2012 11:14:01
Boehringer Ingelheim says it is on growth path, as 2011 sales rise 6.2%Boehringer Ingelheim says it is on growth path, as 2011 sales rise 6.2% The Pharma Letter Both the new launches of Pradaxa dabigatran etexilate and established medicines, such as Spiriva tiotropium , Micardis telmisartan and Combivent ipratropium and salbutamol showed very gratifying growth, said Hubertus von Baumbach, ... Boehringer Sees Sales Rising Further As 2011 Profit Surges Boehringer Ingelheim on growth path - Successful 2011 financial year
25 Apr 2012 06:50:19
Wirtschaft: Boehringer wächst aus eigener Kraft B2B Deutschland Wirtschaft: Boehringer w chst aus eigener Kraft sueddeutsche.de Erfolgreichstes Produkt ist das Lungenpr parat Spiriva, gefolgt vom Blutdrucksenker Micardis und dem Asthma-Mittel Combivent. Erfolgreich eingef hrt wurde der Gerinnungshemmer Pradaxa, w hrend das Patent von Sifrol ablief. Bei Boehringer geht es wieder bergauf Neue Arzneimittel befl geln Boehringer Ingelheim Boehringer Ingelheim auf Wachstumskurs - Erfolgreiches Gesch ftsjahr 2011 |
|
Choose Your language:
Recherche sur le site
Testimonials
Merci bien. J'ai reçu les comprimés et je les ai essayés. Alors j'suis tellement heureux, moi et ma copine aussi. Merci !! DN
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Bestsellers|Politique|Questions fréquentes|Testimonials|Contactez-nous|Sitemap |
|
|
|
|
| |